Avid Bioservices Inc (CDMO)

[vinmantoo]

Citing older adjunctive chemo agents as a rescue of downstream I/O 1.0 agents is not a strong argument.

Tamoxifen, Xtandi or Herceptin are not chemo.

There are two kinds ways to achieve synergy, those which hit the same pathway by different means (anti-PD1 + anti-PD-L1), and those using different pathways (Xtandi, Tamoxifen or Herceptin + anti-PD1 or anti-PD-L1). While there is no proof the combinations of the second kind will generate hoped-for synergies, each agent shows reasonable efficacy on their own. This is in stark contrast to Bavi. I gave you my opinion and stated why. By the way, what I suggested is already being funded by companies in clinical trials, or about to be funded, which is also in stark contrast to Bavi.